Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Clearside Biomedical Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CLSD
Nasdaq
8731
https://clearsidebio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Clearside Biomedical Inc
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors
- Apr 16th, 2024 11:05 am
Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
- Apr 2nd, 2024 11:05 am
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer
- Mar 18th, 2024 11:05 am
Clearside Biomedical Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
- Mar 14th, 2024 10:18 am
Clearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2023 Earnings Call Transcript
- Mar 13th, 2024 12:30 pm
Q4 2023 Clearside Biomedical Inc Earnings Call
- Mar 13th, 2024 10:38 am
Clearside Biomedical Inc (CLSD) Reports Significant Licensing Revenue Growth in Q4 and Full ...
- Mar 12th, 2024 9:35 pm
Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Mar 12th, 2024 8:05 pm
These 2 ‘Strong Buy’ Penny Stocks Could Surge Over 200%, Say Analysts
- Mar 6th, 2024 7:25 pm
Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024
- Feb 29th, 2024 12:05 pm
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
- Feb 25th, 2024 6:37 pm
Pleasing Signs As A Number Of Insiders Buy Clearside Biomedical Stock
- Feb 9th, 2024 10:54 am
Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering
- Feb 7th, 2024 1:00 pm
Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
- Dec 14th, 2023 12:05 pm
Can Clearside Biomedical (NASDAQ:CLSD) Afford To Invest In Growth?
- Dec 6th, 2023 2:21 pm
Clearside Biomedical, Inc. (NASDAQ:CLSD) Q3 2023 Earnings Call Transcript
- Nov 14th, 2023 2:11 pm
Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update
- Nov 13th, 2023 9:05 pm
Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference
- Nov 8th, 2023 12:05 pm
Clearside Biomedical’s Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting
- Nov 7th, 2023 9:20 pm
BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside’s Proprietary SCS Microinjector®
- Nov 3rd, 2023 4:00 pm
Scroll